MargotAnneChimaMDFAAD(She/Her)

Dermatology • New York, NY

Margot Chima at Mount Sinai Dermatology

Join to view full profile

Dr. Chima is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Chima's full profile

Already have an account?

Office
1424 Madison Ave.
New York, NY 10029
Phone+1 212-241-6500
Is this information wrong?

Education & Training

Icahn School of Medicine at Mount SinaiChief Residency, Dermatology, 2021 - 2022
Icahn School of Medicine at Mount SinaiResidency, Dermatology, 2019 - 2022
Icahn School of Medicine at Mount SinaiFellowship, Dermatopharmacology, 2017 - 2019
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 2016 - 2017
University of Nebraska College of MedicineClass of 2016
The University of MichiganBS, Anthropology-Zoology, 2006 - 2010

Certifications & Licensure

NY State Medical License 2017 - 2024
American Board of Dermatology Dermatology

Clinical Trials

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) Start of enrollment: 2012 May 18
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Start of enrollment: 2015 May 26
Completed
Phase 3
Secukinumab for Treatment of Atopic Dermatitis Start of enrollment: 2015 Nov 01
Completed
Phase 2
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Start of enrollment: 2015 Oct 15
Active, not recruiting
Phase 3
A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata Start of enrollment: 2016 Jan 01
Completed
Phase 2
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris Start of enrollment: 2017 Feb 15
Completed
Phase 3
A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis Start of enrollment: 2016 Oct 25
Completed
Phase 2
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata Start of enrollment: 2016 Dec 15
Completed
Phase 2
Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis Start of enrollment: 2016 Dec 19
Completed
Phase 1
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Start of enrollment: 2016 Dec 01
Completed
Phase 2
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) Start of enrollment: 2017 Feb 27
Completed
Phase 3
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis Start of enrollment: 2017 Feb 28
Completed
Phase 1
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Start of enrollment: 2017 Mar 21
Completed
Phase 3
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Start of enrollment: 2017 Jul 18
Terminated
Phase 1, Phase 2
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Start of enrollment: 2017 Jun 07
Completed
Phase 2
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Start of enrollment: 2017 Apr 14
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata Start of enrollment: 2017 Aug 09
Completed
Phase 2
A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis Start of enrollment: 2017 Apr 12
Completed
Phase 1
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) Start of enrollment: 2017 Jun 12
Completed
Phase 3
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis Start of enrollment: 2017 Jul 03
Completed
Phase 2
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis Start of enrollment: 2018 Mar 28
Completed
Phase 3
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) Start of enrollment: 2017 Nov 17
Completed
Phase 3
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) Start of enrollment: 2018 Jan 09
Completed
Phase 2
Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies Start of enrollment: 2017 Oct 31
Completed
Phase 4
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2018 Jan 30
Completed
Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants Start of enrollment: 2018 Jul 11
Active, not recruiting
Phase 3
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Start of enrollment: 2018 Jun 26
Completed
Phase 3
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Jun 27
Terminated
Phase 3
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) Start of enrollment: 2018 Aug 13
Active, not recruiting
Phase 3
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Start of enrollment: 2018 Sep 21
Completed
Phase 2
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Sep 29
Terminated
Phase 2
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Oct 22
Completed
Phase 2
PF-06651600 for the Treatment of Alopecia Areata Start of enrollment: 2018 Dec 03
Completed
Phase 2, Phase 3
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2018 Nov 12
Terminated
Phase 2
Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis Start of enrollment: 2018 Dec 18
Completed
Phase 2
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) Start of enrollment: 2019 Jun 11
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

9 citations
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.
Yael Renert-Yuval, Ana B Pavel, Ester Del Duca, Paola Facheris, Angel D Pagan, Swaroop Bose, Pedro J Gómez-Arias, Michael Angelov, Jennifer Bares, Margo Chima, Yeriel ...> ;Allergy. 2023 Apr 1
6 citations
Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
Yael Renert-Yuval, Joel Correa da Rosa, Sandra Garcet, Ana B Pavel, Jennifer Bares, Margot Chima, Jason E Hawkes, Patricia Gilleaudeau, Mary Sullivan-Whalen, Giselle K...> ;The British Journal of Dermatology. 2022 Oct 1
10 citations
Distinct skin microbiome community structures in congenital ichthyosis.
Khek-Chian Tham, Rachel Lefferdink, Kaibo Duan, Seong Soo Lim, X F Colin C Wong, Erin Ibler, Benedict Wu, Hajar Abu-Zayed, Stephanie M Rangel, Ester Del Duca, Mashkura...> ;The British Journal of Dermatology. 2022 Oct 1
5 citations
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in ...
Hee J Kim, Ester Del Duca, Ana B Pavel, Giselle K Singer, Brian J Abittan, Margot A Chima, Grace Kimmel, Jennifer Bares, Danielle Baum, Matthew Gagliotti, Jordan Genec...> ;Archives of Dermatological Research. 2023 Mar 1
4 citations
Refractory Dissecting Cellulitis of the Scalp Treated With Risankizumab.
Folawiyo Babalola, Margot Chima, Ruth Jobarteh, Alice Gottlieb> ;Journal of Drugs in Dermatology. 2022 Mar 1
17 citations
Secukinumab responses vary across the spectrum of congenital ichthyosis in adults.
Rachel Lefferdink, Stephanie M Rangel, Margot Chima, Erin Ibler, Ana B Pavel, HeeJin Kim, Benedict Wu, Hajar Abu-Zayed, Jianni Wu, Kathryn Jackson, Giselle Singer, Kei...> ;Archives of Dermatological Research. 2023 Mar 1
42 citations
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Emma Guttman-Yassky, Yael Renert-Yuval, Jennifer Bares, Margot Chima, Jason E. Hawkes, Patricia Gilleaudeau, Mary Sullivan-Whalen, Giselle Singer, Sandra Garcet, Ana B...> ;Allergy. 2021 Sep 6
1 citations
Wound Healing Treatments After Ablative Laser Skin Resurfacing: A Review.
Hayley Leight-Dunn, Margot Chima, Elika Hoss> ;Journal of Drugs in Dermatology. 2020 Nov 1
6 citations
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study.
H. Kim, Giselle Singer, Brian J. Abittan, Margot Chima, Grace Kimmel, Jennifer Bares, Matthew Gagliotti, Jordan Genece, Justin Chu, Gregory E. Wilding, Mark Lebwohl> ;Journal of the American Academy of Dermatology. 2021 Jan 10
61 citations
Phase 2 Randomized, Double-blind Study of IL-17-Targeting with Secukinumab in Atopic Dermatitis
Benjamin Ungar, Ana B. Pavel, Randall Li, Grace Kimmel, John K Nia, Peter W Hashim, Hee Jin Kim, Margot Chima, Anjali S. Vekaria, Yeriel Estrada, Hui Xu, Xiangyu Peng,...> ;The Journal of Allergy and Clinical Immunology. 2021 Jan 1
21 citations
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial.
Peter W Hashim, Margot Chima, H. Kim, Jennifer Bares, Christopher J. Yao, Giselle Singer, Tinley Chen, Jordan Genece, Danielle Baum, Grace Kimmel, John K Nia, Matthew ...> ;Journal of the American Academy of Dermatology. 2020 Feb 1
28 citations
Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases.
Tali Czarnowicki, Helen He, Alexandra Leonard, Hyun Je Kim, Naoya Kameyama, Ana B. Pavel, Randall Li, Yeriel Estrada, Huei-Chi Wen, Grace Kimmel, H. Kim, Margot Chima,...> ;The Journal of Allergy and Clinical Immunology. 2019 Jun 1
30 citations
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
Grace Kimmel, Margot Chima, Hee Jin Kim, Jennifer Bares, Christopher J. Yao, Giselle Singer, Soo Jung Kim, Jerry Bagel, Mark Lebwohl> ;Journal of the American Academy of Dermatology. 2019 May 10
29 citations
TNF inhibitors for psoriasis.
Margot Chima, Mark Lebwohl> ;Seminars in Cutaneous Medicine and Surgery. 2018 Sep 1
26 citations
Oral contraceptives cause evolutionarily novel increases in hormone exposure: A risk factor for breast cancer.
Jennie L Lovett, Margo A Chima, Juliana K Wexler, Kendall J Arslanian, Andrea B Friedman, Chantal B Yousif, Beverly I. Strassmann> ;Evolution, Medicine, and Public Health. 2017 Jan 1
5 citations
Does student performance on preclinical OSCEs relate to clerkship grades
Margot Chima, Gary L. Beck Dallaghan> ;Medical Education Online. 2016 Jun 22
Join now to see all

Books/Book Chapters

Comprehensive Dermatologic Drug Therapy
Chapter: IL-17A inhibitors
Page 312 - 320Chima, Margot; Lebwohl, MarkEditors: Wolverton.ElsevierEdition 4,2021

Hospital Affiliations

The Mount Sinai HospitalNew York, New York

MargotAnneChimaMDFAAD(She/Her)

Dr. Chima is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.